Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04523480 · ClinicalTrials.gov registry record · Phase 3

Testopel ® vs. Generic Testosterone Pellets.

A Phase 3 study of Hypogonadism, sponsored by University of Miami.

Completed
Registry status
Phase 3
Development phase
75
Enrollment target
1
Study location

NCT04523480 is a Phase 3 study of Hypogonadism that has completed, run by University of Miami. The registered enrollment target is 75 participants, below the 117-participant average among 21 other Hypogonadism trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04523480, a Phase 3 study of Hypogonadism, has completed, sponsored by University of Miami.

COMPLETED
Registry status
Phase 3
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hypogonadism.

Conditions Studied

Interventions

  • DRUG Testopel 75mg Drug Implant
  • DRUG Testopel 100mg Drug Implant
  • DRUG Testopel 200mg Drug Implant

Study Locations (1)

Florida

  • University of Miami, Department of Urology - Miami

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2020-03-12
Est. Completion 2022-12-20
Phase Phase 3

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT04523480

The ClinicalTrials.gov registry entry for NCT04523480 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 21 other Hypogonadism trials with a reported enrollment target (36% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 3 interventions - of which Testopel 75mg Drug Implant is the first listed.

NCT04523480 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04523480 about?

NCT04523480 is a clinical study titled "Testopel ® vs. Generic Testosterone Pellets.". The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hy...

What is the current status of trial NCT04523480?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2020-03-12. Estimated completion is 2022-12-20.

What conditions does trial NCT04523480 study?

This clinical trial studies the following conditions: Hypogonadism.

What interventions are being tested in trial NCT04523480?

The interventions under investigation include: Testopel 75mg Drug Implant (DRUG), Testopel 100mg Drug Implant (DRUG), Testopel 200mg Drug Implant (DRUG).

Who is sponsoring clinical trial NCT04523480?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04523480 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypogonadism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.